Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in overweight or obese women with polycystic ovary syndrome
ChiCTR2400081361Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- Feb 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polycystic ovary syndrome (PCOS) comparing HRS9531 Group with Placebo Group (2 arms). Primary endpoints: Menstrual frequency and Weight. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
HRS9531
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ChiCTR2400081361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081361.